Stockreport

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

BeOne Medicines Ltd. - American Depositary Shares  (ONC) 
PDF Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL)BeOne to [Read more]